MDVN : Analysis & Opinions

  1. Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst ...

    January 23, 2015
    Medivation Inc. (MDVN) and partner Astellas Pharma Inc.'s (ALPMY) Xtandi met the primary endpoint in a phase II study (TERRAIN) ...
  2. Medivation, Inc. (MDVN): New Analyst Report from Zacks Equity ...

    December 29, 2014
    Medivation posted EPS of $0.96 in the third quarter of 2014, turning around the year-ago loss of $0.18 per share but falling ...
  3. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  4. Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst ...

    December 23, 2014
    Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement ...
  5. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  6. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  7. It's No Accident That Drugs Are Expensive

    August 30, 2013
    Branded drugs are expensive in large part because it's expensive and risky to develop them
  8. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  9. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  10. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  11. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  12. Biotech Stocks With Bullish Trends From Short Sellers

    March 26, 2012
    One of the clearest sentiment indicators comes from short sellers. Changes in the number of shares shorted over time can ...
  13. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  14. The Best And Worst Stocks For The Year

    August 2, 2010
    Ten stocks have climbed 200% since New Year’s, while more than 25 have lost over half their value.
  15. 3 Biotech Stocks On The Move

    March 10, 2010
    All three of these biotech companies are swinging for the fences and this approach has been reflected in their stock prices.
Trading Center